Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.

Andres-Ejarque, Rosa; Ale, Hira Bahadur; Grys, Katarzyna; Tosi, Isabella; Solanky, Shane; Ainali, Chrysanthi; Catak, Zeynep; Sreeneebus, Hemawtee; Saklatvala, Jake; Dand, Nick; de Rinaldis, Emanuele; Chapman, Anna; Nestle, Frank O; Barnes, Michael R; Warren, Richard B; Reynolds, Nick J; Griffiths, Christopher E M; Barker, Jonathan N; Smith, Catherine H; Di Meglio, Paola

View / Open Files

Published version (PDF, 375Kb)

Authors

Andres-Ejarque, Rosa

Ale, Hira Bahadur

Grys, Katarzyna

Tosi, Isabella

Solanky, Shane

Ainali, Chrysanthi

Catak, Zeynep

Publication Date

2021-12-16

Journal Title

Nature communications

ISSN

2041-1723

Volume

Issue

Language

eng

Type

Other

This Version

VoR

Metadata

Show full item record

Citation

Andres-Ejarque, R., Ale, H. B., Grys, K., Tosi, I., Solanky, S., Ainali, C., Catak, Z., et al. (2021). Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.. [Other]. https://doi.org/10.1038/s41467-021-27447-6

Identifiers

34916493, PMC8677717

External DOI: https://doi.org/10.1038/s41467-021-27447-6

This record's DOI: https://doi.org/10.17863/CAM.80746

Rights

Attribution 4.0 International

Licence URL: https://creativecommons.org/licenses/by/4.0/

Statistics

Total file downloads (since January 2020). For more information on metrics see the IRUS guide.

Except where otherwise noted, this item's licence is described as Attribution 4.0 International